CASI, a US-Beijing pharma, out-licensed China marketing rights for Evomela® (melphalan hydrochloride for injection) in China to China Resources Guokang Pharma. In December 2018, Evomela® was approved in China for two multiple myeloma conditions following NMPA priority review. Terms of the agreement were not disclosed. Previously Melphalan was not available for multiple myeloma patients in China. CASI acquired China rights to the drug from US-based Spectrum in 2014 as part of a three drug deal.
Source: China Biotoday
